I agree...if they have to try again, 2 years seems appropriate to re-characterize, redo the manufacturing process, run immunogenicity trials and submit data, and for the FDA to complete their review process.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.